Oscar Health remains a Buy despite recent 7% drop, driven by strong growth outlook and insider buying.

Oscar Health's stock has dropped 7% recently but remains a Buy due to management's optimistic 61% growth guidance and insider buying by the CEO, which signals confidence in the company's future. Risks include market volatility, potential failure to meet growth targets, and sensitivity to interest rates as a small-cap, high-beta stock. The analyst believes favorable tailwinds could support a positive price rebound and multiple expansion if growth targets are met.